BioHarvest Sciences Inc. Common Stock Q2 2026 Earnings Call Summary
BioHarvest Sciences reported a Q2 2026 earnings call focused on shifting capital from D2C to CDMO. It secured a CDMO manufacturing and supply deal for a rare fragrance, targeting $20m to $30m revenue in 2027-2028 and $180m over five years, with limited production in H1 2027. 2026 revenue guidance was cut to $37m-$40m, and it expects CDMO EBITDA loss of $1.5m-$2.5m and consolidated EBITDA breakeven in 2027.
How this was made
The 30-second read
Why it matters
Traders can update valuation models around (1) the 2026 revenue guide cut, (2) the expected timing of commercial production in H1 2027, and (3) the path to consolidated EBITDA breakeven in 2027, with fragrance revenue projected for 2027-2028.
Market read
The call combines a downside 2026 revenue reset with upside optionality from a new CDMO fragrance contract and a stated 2027 EBITDA breakeven target, creating a mixed but tradable setup.
What to watch
D2C revenue guidance was reduced due to media inflation, and the call’s success depends on execution of smaller bioreactors in H1 2027 and avoiding future equity funding.
Background
BioHarvest’s Q2 2026 earnings call summary describes a strategic pivot from D2C toward CDMO manufacturing capacity, supported by a new fragrance supply agreement and non-dilutive AI funding.
Market effects
Highlights a CDMO/royalty model for biotech ingredients, potentially reinforcing investor focus on manufacturing scalability and non-dilutive funding.
Israel Innovation Authority non-dilutive funding mention may support sentiment around Israeli biotech support programs.
Rare fragrance manufacturing deal underscores cross-border ingredient supply chains and contract manufacturing demand.
Counterpoint
The fragrance deal’s economics are still partially under negotiation (royalty percentages), so the revenue/EBITDA trajectory may be less certain than the headline targets imply.
Key entities
- issuerBioHarvest Sciences Inc.
Announced a first-ever CDMO manufacturing and supply agreement for a rare premium fragrance, revised 2026 revenue guidance, and provided 2027-2028 outlook.
- funderIsrael Innovation Authority
Provided non-dilutive funding to integrate AI and machine learning into biological development workflows.
- partnerTate & Lyle
Referenced in an expanded model where large-volume partners build their own facilities while BioHarvest provides technology transfer for royalties.
